Liminatus Pharma, Inc. (LIMN): Completion of Acquisition or Disposition of Assets
Liminatus Pharma, Inc. (LIMN) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. EX-2.1 2 tm2619730d1_ex2-1.htm EXHIBIT 2.1 Exhibit 2.1 AMENDED AND RESTATED MERGER AGREEMENT dated June 29, 2026 by and among InnocsAI LLC, Delaware limited liability company (the “ Company ”), NamChul Jung, as the Members’ Representative (the “ NamChul Jung ”), and Liminatus Pha
How this was made
The 30-second read
Why it matters
Completion of the merger changes LIMN’s exposure to CAR-T therapy technologies and related IP, and it introduces deal consideration mechanics (large common-stock issuance plus CVRs) that can affect valuation and trading liquidity.
Market read
Deal completion plus explicit consideration terms (1.6B shares at $0.20 and CVRs) are actionable for repricing dilution and contingent upside/downside.
What to watch
Traders should focus on (1) the final CVR definition/valuation, (2) whether the 1.6B share issuance implies meaningful ownership dilution, and (3) any contingent liabilities or IP/clinical risk transferred with the acquired CAR-T technology.
Background
The 8-K references an amended and restated merger agreement dated June 29, 2026, where InnocsAI LLC merges into a wholly owned subsidiary of Liminatus Pharma.
Ticker impact
Liminatus Pharma’s 8-K states Item 2.01 completion of an asset acquisition/disposition via an amended and restated merger agreement.
Near-term volatility possible as investors reprice deal economics (stock issuance and CVR terms), but direction depends on deal value vs dilution and CVR structure.
The filing confirms completion and specifies the consideration mechanics (1.6B shares at $0.20 plus CVRs), which can drive dilution/CVR expectations even without further deal valuation details in the excerpt.
Market effects
CAR-T technology M&A read-through: continued consolidation/asset transfers can affect deal expectations and valuation benchmarks for small-cap cell-therapy IP holders.
No clear regional macro linkage in the provided text.
Limited based on excerpt; deal is described as CAR-T IP-related with no cross-border regulatory or jurisdictional specifics shown.
Counterpoint
The excerpt lacks the CVR economics and any disclosed valuation rationale; the market may treat this as largely dilution-driven until CVR terms and post-close integration details are clarified.
Key entities
- public_companyLiminatus Pharma, Inc.
Purchaser in the amended and restated merger agreement; subject of the 8-K and recipient of the completed transaction.
- private_companyInnocsAI LLC
Company being merged into a wholly owned subsidiary of LIMN; operates in CAR-T therapy technologies and related IP.
- individualNamChul Jung
Members’ representative named in the merger agreement.
